Plasma proteomic study of acute-on-chronic liver failure

Study on the regulation mechanism of MICB mediated NK cell signaling pathwany in patients with acute-on-chronic liver failure

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042896

Enrollment

Unknown

Registered

2021-01-31

Start date

2021-01-18

Completion date

Unknown

Last updated

2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute-on-chronic liver failure

Interventions

Acute on chronic liver failure group and chronic hepatitis group:Nil

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with acute-on-chronic liver failure admitted to the department of infectious; 2. According to the guidelines for the diagnosis and treatment of liver failure (2018 Edition) issued by the liver failure and artificial liver group of infectious diseases branch of Chinese Medical Association and the severe liver disease and artificial liver group of Hepatology branch of Chinese Medical Association in 2018, it meets the diagnostic criteria of acute-on-chronic liver failure. 3. Aged > 16 years old or < 65 years; 4. The subject or legal representative is willing to enter the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined with tumor diseases; 2. Previous diagnosis of other organ failure (heart failure, respiratory failure, renal failure, etc.) in Grade 3A hospital.

Design outcomes

Primary

Measure	Time frame
Proteomics;	—

Countries

China

Contacts

Public ContactZhang Qian

Affiliated Hospital of Southwest Medical University

782872184@qq.com+86 15984036700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026